[The phase II clinical trial of Seratia Marcescens Anticancer Vaccine (S311) for malignant pleural effusions].
To evaluate the effect and adverse reactions of Seratia Marcescens Anticancer Vaccine ( S311) in the treatment of malignant pleural effusions. 0. 32 mg of S311 was administered into intracavity once a week, for successive three weeks, after draining off the pleural cavity completely by thoracocentesis or chest drainage. Two hundred and forty-one patients with malignant effusions finished the arrangement of S311 therapy. The overall response rate was 92. 1%. The main adverse reactions were fever and pleuritic pain. Some patients had chill, dyspnea, nausea and vomiting. Liver dysfunction was observed in a few cases. S311 is an effective drug for malignant pleural effusions.